← RHYTHM PHARMACEUTICALS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 | $3.2m |
$23.6m
+649.46%
|
$77.4m
+227.56%
|
$130.1m
+68.06%
|
$189.8m
+45.83%
|
$239.9m
+26.43%
|
|
| Cost of Revenue | $19.6m |
$22.9m
+16.84%
|
$50.3m
+119.87%
|
$109.5m
+117.43%
|
$90.5m
-17.36%
|
$599k
-99.34%
|
$2.1m
+256.09%
|
$9.3m
+336.10%
|
$13.4m
+43.71%
|
$19.5m
+45.81%
|
$26.4m
+35.38%
|
|
| Gross Profit (Calculated) (derived) | ($19.6m) |
($22.9m)
-16.84%
|
($50.3m)
-119.87%
|
($109.5m)
-117.43%
|
($90.5m)
+17.36%
|
$2.6m
+102.82%
|
$21.5m
+741.68%
|
$68.1m
+216.79%
|
$116.8m
+71.39%
|
$170.3m
+45.83%
|
— | |
| Research and Development Expense | $19.6m | $22.9m | $50.3m | $109.5m | $90.5m | $104.1m | $108.6m | $135.0m | $238.0m | $167.3m | $173.2m | |
| Selling, General and Administrative Expense | $6.3m | $9.5m | $28.1m | $36.5m | $46.1m | $68.5m | $92.0m | $117.5m | $144.3m | $194.9m | $240.9m | |
| Labor and Related Expense | $2.7m | — | — | — | — | — | — | — | — | — | — | |
| Amortization of Intangible Assets | — | — | — | — | — | $342k | $774k | $855k | — | — | — | |
| Operating Lease, Expense | — | — | — | $629k | $551k | $551k | $551k | $551k | — | — | — | |
| Operating Expenses | $25.9m | $32.4m | $78.4m | $146.0m | $136.6m | — | — | — | — | — | $440.5m | |
| Operating Income (Loss) | ($25.9m) |
($32.4m)
-25.12%
|
($78.4m)
-141.94%
|
($146.0m)
-86.18%
|
($136.6m)
+6.46%
|
($170.1m)
-24.52%
|
($179.2m)
-5.35%
|
($184.4m)
-2.90%
|
($265.5m)
-44.02%
|
($192.0m)
+27.68%
|
($200.6m)
-4.49%
|
|
| Investment Income, Net | — | — | — | — | — | — | $4.0m | $13.9m | $14.7m | $15.3m | — | |
| Other Nonoperating Income (Expense) | — | — | — | — | — | — | ($790k) | $190k | $2.2m | $1.3m | — | |
| Interest Expense (non-operating) | — | — | — | — | — | — | $5.2m | $13.9m | $20.6m | $20.6m | $18.5m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | — | — | — | — | $69.6m | $181.1m | ($178.7m) | ($258.9m) | ($196.1m) | ($204.3m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $69.6m | $181.1m | ($184.1m) | ($260.3m) | ($196.0m) | ($204.3m) | |
| Income Tax Expense (Benefit) | — | — | — | — | — | — | — | $564k | $346k | $497k | $1.1m | |
| Net Income (Loss) Attributable to Parent | ($29.1m) |
($37.6m)
-29.26%
|
($74.1m)
-97.07%
|
($140.7m)
-90.01%
|
($134.0m)
+4.78%
|
($69.6m)
+48.05%
|
($181.1m)
-160.18%
|
($184.7m)
-1.97%
|
($260.6m)
-41.11%
|
($196.5m)
+24.58%
|
($210.2m)
-6.96%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | ($29.1m) |
($37.6m)
-29.26%
|
($74.1m)
-97.07%
|
($140.7m)
-90.01%
|
($134.0m)
+4.78%
|
($1)
+100.00%
|
($3)
-147.86%
|
($3)
+7.78%
|
($264.6m)
-8267874900.00%
|
($201.9m)
+23.68%
|
($210.2m)
-4.11%
|
|
| Earnings Per Share, Basic | — | — | — | ($3.86) | ($3.04) | ($1.40) | ($3.47) | ($3.20) | ($4.34) | ($3.11) | ($3.12) | |
| Earnings Per Share, Diluted | — | — | — | ($3.86) | ($3.04) | ($1.40) | ($3.47) | ($3.20) | ($4.34) | ($3.11) | ($3.12) | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 36.4m | 44.1m | 49.6m | 52.1m | 57.7m | 61.0m | 65.0m | 67.4m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 36.4m | 44.1m | 49.6m | 52.1m | 57.7m | 61.0m | 65.0m | 67.4m | |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related Costs | — | — | — | — | — | — | $62k | — | — | — | — | |
| Costs and Expenses | — | — | — | — | — | $173.2m | $202.8m | $261.8m | $395.6m | $381.8m | — |